

Save the date

15 & 16th

March

2017

1st edition

Washington DC
USA

Primary Hypertension Guidelines **Forum**

Better understand the Primary
Hypertension Guidelines
development process and its implications

GUIDELINES
FORUM by TMA
PRIMARY HYPERTENSION



Know more about Primary Hypertension Guidelines development process and its implications

The Translational Medicine Academy (TMA) is an international academic Foundation with focused activities in Mission Critical Areas of high public health importance having significant professional and patient therapeutic and educational gaps.

Why a Primary Hypertension Guidelines Forum®?

The Translational Medicine Academy has developed a model for creating an original space between experts to exchange upon guidelines in different therapeutic areas.

The quality of research and development efforts made by industrial companies in biomarkers, pharmacological agents, and medical devices has obviously had a major impact on the position of these products in clinical guidelines on the management of Primary Hypertension.

Success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development. And, ultimately, guidelines really shape clinical practice if doctors and their patients adopt them.

A better understanding of the processes involved in guidelines development and implementation will help companies that develop drugs, biomarkers and devices, to adapt and improve their research and development programs for the future. This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

Forum objectives

To have an in depth discussion between experts about hypertension therapy guidelines for the common interest of stakeholders during a closed meeting

- To focus on most advanced knowledge
- To identify gaps in treatment
- To improve the development and utilization of guidelines
- To develop “field guidelines” that are applicable to ethnically and racially diverse populations with different co-morbidities and hypertension profiles
- To develop risk equations for specific geographies/populations
- To create genetic profiles for specific geographies/populations to better understand responsiveness to therapies

Format

A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.

Who should attend ?

Industry representatives, clinical research organizations, health insurance system professionals, pharmacy benefits managers and all those interested in Primary Hypertension from a scientific, regulatory, educational and cost-benefit management perspective.

An opportunity to meet a panel of international scientific experts

THE FACULTY IS CO-CHAIRD BY



Prof. William T. Abraham

- Professor of Internal Medicine, Physiology and Cell Biology
- Chair of Excellence in Cardiovascular Medicine
- Chief, Division of Cardiovascular Medicine
- Associate Dean for Clinical Research
- Medical Director, Clinical Trials Management Office
- Deputy Director, Dorothy M. Davis Heart and Lung Research Institute
- The Ohio State University, Columbus, Ohio - USA



Prof. Michael Weber

- Professor of medicine , SUNY Downstate College of Medicine ,New York – USA
- Editor-in-chief of The Journal of Clinical Hypertension
- Member of the executive committee for the International Society of Hypertension
- Member of the board of directors for the Center for Medicine in the Public Interest



Prof. Bryan Williams

- Chair of Medicine at University College London - UK
- Director of the NIHR UCLH/ UCL Biomedical Research Centre and Director of Research at UCL Hospitals
- Consultant Physician at UCL Hospitals
- NIHR Senior Investigator

It will include a Faculty of 15-20 experts, either reviewers, regulatory specialists, and recognized international experts from Europe, North America and Asia.

Who you may listen to

- Faculty to be confirmed -

- Professor Kazuomi Kario: Jichi Medical University School of Medicine - Shimotsuke-shi, Tochigi-ken - Japan
Talk: « Hypertension in Asia? »
- Professor Andre P. Kengne - Cape Town Cardiology, Epidemiology, Diabetology
Talk: « Hypertension in Africa »
- Professor Graham MacGregor - Chairman - Professor of Cardiovascular Medicine at the Wolfson Institute of Preventive Medicine (Barts & The London) **Talk: « hypertension and diet »**
- Professor Daniel T. Lackland - MUSC Health Charleston, South Carolina
- Professor Ji-Guang Wang - Shanghai Jiaotong University School of Public Health - Shanghai, China
- Dr. Philip B. Gorelick: - Medical Director of the Hauenstein Neuroscience Center, Saint Mary's Health Care, Grand Rapids, MI
Talk: « Hypertension and Stroke »
- Professor Bryan Williams - bryan.williams@ucl.ac.uk
Talk: « What to do with the young hypertensive people? »
- Professor Eoin O'Brien Professor Molecular Pharmacology - Conway Institute - UCD Belfield - Dublin
- Prof. Jean-Jacques MOURAD
- Atul PATHAK
- Michel Azizi
- Fayez Zanad
- Henry Black

Interested in going further on Primary Hypertension ?

Ongoing programs

Participate in post forum activities with TMA.

We offer you the opportunity to go further on Prevention and Management with our dedicated programs (part of TMA Mission Areas plans).

Our team can propose you the most convenient activities, that TMA is developing, on request.

Contact us

TMA Foundation
Charles Schoen
Tel.: +33 (0) 6 08 18 77 08
Email: charles.schoen@tmacademy.org

Grant Opportunities (including CME, Advisory Boards & Customized Grants)
Yann Colardelle / William Melhuish
Tel.: + 33 (0) 6 16 54 81 57
E-mail : yanncol@tmacademy.org

Organization:
Anne-Sophie Squiban
Tel: + 33 (0)6 74 52 37 09
Email : annesophie.squiban@tmacademy.org

Registration : www.tmacademy.org

